Finance News

Arrowhead Pharmaceuticals to Webcast 2017 Fiscal Year End Results

2.7 from 3 votes
Wednesday, December 06, 2017

PASADENA, Calif.  - Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced that it will host a webcast and conference call on Tuesday, December 12, 2017, at 4:30 p.m. EST to discuss its financial results for the 2017 fiscal year ended September 30, 2017.

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 6977547.

A replay of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 6977547.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit


Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
Phone: 626-304-3400
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
Phone: 212-915-2578

Source: Arrowhead Pharmaceuticals, Inc.
2.7 from 3 votes
Free Newsletter
by Abidemi Uruejoma
by Abidemi Uruejoma
by Abidemi Uruejoma